<DOC>
	<DOCNO>NCT02891408</DOCNO>
	<brief_summary>The primary objective study evaluate single-dose pharmacokinetics ( PK ) GS-0976 adult normal hepatic function , mild , moderate , severe hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics GS-0976 Adults With Normal Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Cohort 1 ( Mild Hepatic Impairment ) : Male nonpregnant/nonlactating female , age 1870 year inclusive mildly impaired normal hepatic function . Individuals current nonsmoker ( use tobacco , nicotinecontaining tetrahydrocannabinol ( THC ) containing product within last 14 day ) . Each individual control group match age ( ± 10 year ) , gender , race , body mass index ( ± 15 % 18 &lt; body mass index ( BMI ) &lt; 36 kg/m^2 ) individual mild hepatic impairment group . Individuals mild hepatic impairment must score 56 ChildPughTurcotte ( CPT ) Classification screening , diagnosis chronic ( &gt; 6 month ) , stable hepatic impairment clinically significant change within 3 month ( 90 day ) prior study drug administration ( Day 1 ) . Cohort 2 ( Moderate Hepatic Impairment ) : Male nonpregnant/nonlactating female , age 1870 year inclusive moderately impaired normal hepatic function . Individuals current nonsmoker ( use tobacco , nicotinecontaining THCcontaining product within last 14 day ) . Each individual control group match age ( ± 10 year ) , gender , race , body mass index ( ± 15 % 18 &lt; BMI &lt; 36 kg/m^2 ) individual moderate hepatic impairment group . Individuals moderate hepatic impairment must score 79 CPT Classification screening , diagnosis chronic ( &gt; 6 month ) , stable hepatic impairment clinically significant change within 3 month ( 90 day ) prior study drug administration ( Day 1 ) . Cohort 3 ( Severe Hepatic Impairment ) : Male nonpregnant/nonlactating female , age 1870 year inclusive severely impaired normal hepatic function . Individuals current nonsmoker ( use tobacco , nicotinecontaining THCcontaining product within last 14 day ) . Each individual control group match age ( ± 10 year ) , gender , race , body mass index ( ± 15 % 18 &lt; BMI &lt; 36 kg/m^2 ) individual severe hepatic impairment group . Individuals severe hepatic impairment must score 1015 CPT Classification screening , diagnosis chronic ( &gt; 6 month ) , stable hepatic impairment clinically significant change within 3 month ( 90 day ) prior study drug administration ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>